A new study published in PLoS One aimed to evaluate the effects of dipeptidyl peptidase-4 inhibitors (DPP-4is) on bone fracture in type-2 diabetes mellitus (T2DM) patients. This was a systematic review and network meta-analysis which entailed a search from Cochrane Library, Embase, Medline, and ClinicalTrials.gov from inception through April 28th, 2016 to identify randomized controlled trials (RCTs) that compared DPP-4is with placebo or other anti-diabetics in T2DM patients. The interventions included 5 DPP-4is (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin), while controls included placebo and five other anti-diabetics (sulfonylureas, glucagon-like peptide-1 receptor agonists, metformin, thiazolidinediones, sodium-glucose co-transporter-2 inhibitors). The results showed that the risk of fracture for alogliptin tended to decrease when compared to placebo. That is, aloglitpin had a lower risk compared with linagliptin and saxagliption. Whereas, vildagliptin could not be correlated to the risk of bone fracture. Hence, the results indicated that vildagliptin did not seem to have an association with the risk of bone fracture.